SeaCrest Wealth Management’s Corcept Therapeutics CORT Stock Holding History

SeaCrest Wealth Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,000	Closed	-$12K	–	773
2019 Q1	$12K	Sell	1,000 -500	-33%	-$6.21K	﹤0.01%	1462
2018 Q4	$20K	Sell	1,500 -5,150	-77%	-$68.1K	﹤0.01%	1229
2018 Q3	$93K	Sell	6,650 -5,300	-44%	-$74.1K	0.02%	767
2018 Q2	$188K	Sell	11,950 -6,300	-35%	-$110K	0.03%	511
2018 Q1	$300K	Sell	18,250 -2,400	-12%	-$44.5K	0.06%	367
2017 Q4	$373K	Buy	+20,650	New	+$374K	0.07%	317

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SeaCrest Wealth Management's CORT Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of Corcept Therapeutics (CORT) in Q2 2019, closing a stake of 1,000 shares — an estimated $12K sold.

SeaCrest Wealth Management first reported a position in CORT in Q4 2017 and held it in 6 quarters. The position peaked at $373K in Q4 2017. 183 funds tracked by Wall St. Rank hold CORT as of Q2 2019.

SeaCrest Wealth Management reported no remaining Corcept Therapeutics position as of Q2 2019 after selling out during the quarter.
SeaCrest Wealth Management sold 1,000 Corcept Therapeutics shares in Q2 2019, an estimated $12K.
SeaCrest Wealth Management first reported a position in Corcept Therapeutics in Q4 2017 and held it in 6 quarters.
SeaCrest Wealth Management's Corcept Therapeutics position peaked at $373K in Q4 2017.
183 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.